(Reuters) -Johnson & Johnson said on Monday it has discontinued a late-stage study testing its experimental drug to treat a ...

Pharma stock Theralase Technologies (TSXV:TLT) announced a significant update on its ongoing bladder cancer clinical study ...

A new study in mice by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) has identified a promising drug ...

A new mouse study has identified a promising drug combination for the treatment of muscle-invasive bladder cancer.

Researchers are a step closer to revolutionizing how doctors use radiotherapy to treat patients with muscle-invasive bladder ...

Johnson & Johnson has discontinued its SunRISe-2 study for TAR-200 in bladder cancer patients not undergoing radical ...

J&J acquired rights to the silicone-based drug delivery service used in TAR-200, which allows for the continuous release of ...

The sun has set on Johnson & Johnson’s SunRISe-2 study. J&J called a halt to the phase 3 bladder cancer trial after an ...

Researchers are a step closer to revolutionising how doctors use radiotherapy to treat patients with muscle-invasive bladder ...

Analyst Sam Slutsky from LifeSci Capital maintained a Buy rating on CG Oncology, Inc. (CGON – Research Report) and keeping the price ...

The 2024 American Society for Radiation Oncology (ASTRO) annual meeting held in Washington D.C., between September 29 and ...

TORONTO, ON / ACCESSWIRE / October 7, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and ...